Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood plasma soothe severe dry eye?

NCT ID NCT07773740

Disease control Sponsor: Gladys Lucia Silva Linares Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This trial tests whether eyedrops made from a patient's own blood plasma, rich in growth factors (PRGF), can reduce symptoms of severe dry eye disease. About 100 adults with severe dry eye will use either PRGF or a placebo solution alongside their standard treatment for one month. The study measures changes in symptoms and several signs of eye health, such as tear film stability and corneal damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PRGF (plasma rich in growth factors) eyedrops
What this could lead to
If PRGF eyedrops prove effective, they could offer a new treatment option for people with severe dry eye disease, potentially reducing symptoms and improving eye comfort.
What could go wrong
This is an early-stage trial, and the results may not show a clear benefit over placebo. The treatment requires frequent application and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any male or female patient over 18 years of age with severe dry eye disease who is prescribed PRGF treatment and presents for consultation between august 2026 and august 2027. * Acceptance to participate in the study and signing of the informed consent form Exclusion Criteria: * Platelet disorders or coagulation abnormalities. * Active systemic infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease with severe keratitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease with severe keratitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.